{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:59:15Z","timestamp":1793059155112,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["12\/RC\/2273"],"award-info":[{"award-number":["12\/RC\/2273"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006628","name":"Mead Johnson Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ebiom.2021.103307","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T05:10:22Z","timestamp":1617340222000},"page":"103307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["The gut microbiome influences the bioavailability of olanzapine in rats"],"prefix":"10.1016","volume":"66","author":[{"given":"Sofia","family":"Cussotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Golubeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Zhdanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conall R.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Fouhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Dinan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall P.","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Cryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan T.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.ebiom.2021.103307_bib0001","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1111\/bph.14366","article-title":"Drug\u2013gut microbiota interactions: implications for neuropharmacology","volume":"175","author":"Walsh","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103307_bib0002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/pr.118.015768","article-title":"Gut reactions: breaking down xenobiotic\u2013microbiome interactions","volume":"71","author":"Clarke","year":"2019","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103307_bib0003","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/03602532.2018.1497647","article-title":"Gut microbiota modulates drug pharmacokinetics","volume":"50","author":"Zhang","year":"2018","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.ebiom.2021.103307_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1291-3","article-title":"Mapping human microbiome drug metabolism by gut bacteria and their genes","author":"Zimmermann","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103307_bib0005","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1172\/JCI72335","article-title":"Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics","volume":"124","author":"Carmody","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ebiom.2021.103307_bib0006","unstructured":"FDA. Statistical approaches to establishing bioequivalence: food and drug administration; 2001 [updated 02-2001. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-approaches-establishing-bioequivalence."},{"key":"10.1016\/j.ebiom.2021.103307_bib0007","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1038\/tp.2013.83","article-title":"Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat","volume":"3","author":"Davey","year":"2013","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103307_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115225","article-title":"The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse","volume":"9","author":"Morgan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2021.103307_bib0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of non-antibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103307_bib0011","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ebiom.2015.10.018","article-title":"Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure","volume":"2","author":"Bahr","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2021.103307_bib0012","article-title":"Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome","author":"Skonieczna-Zydecka","year":"2018","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103307_bib0013","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1124\/dmd.115.064790","article-title":"In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism","volume":"43","author":"Korprasertthaworn","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ebiom.2021.103307_bib0014","unstructured":"FDA. Drug labeling information submitted to the FDA https:\/\/psychopharmacologyinstitute.com\/antipsychotics\/olanzapine\/olanzapine-pharmacokinetics\/. 2019."},{"issue":"6","key":"10.1016\/j.ebiom.2021.103307_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2174\/138920010791636202","article-title":"Atypical antipsychotic metabolism and excretion","volume":"11","author":"Sheehan","year":"2010","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103307_bib0016","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1067\/mcp.2002.119815","article-title":"The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers","volume":"71","author":"Markowitz","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2021.103307_bib0018","first-page":"1","article-title":"Enhanced degradation of lactide-co-glycolide polymer with basic nucleophilic drugs","volume":"2015","author":"D\u2019Souza","year":"2015","journal-title":"Adv Pharm"},{"key":"10.1016\/j.ebiom.2021.103307_bib0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","article-title":"Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: Impact on bioequivalence","volume":"65","author":"Garc\u00eda-Arieta","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ebiom.2021.103307_bib0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.neuroscience.2016.10.003","article-title":"Behavioural and neurochemical consequences of chronic gut microbiota depletion during adulthood in the rat","volume":"339","author":"Hoban","year":"2016","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103307_bib0021","doi-asserted-by":"crossref","first-page":"e97458","DOI":"10.1371\/journal.pone.0097458","article-title":"Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system","volume":"9","author":"Rashid","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103307_bib0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1570-0232(02)00164-2","article-title":"Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection","volume":"773","author":"Dusci","year":"2002","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103307_bib0023","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-4347(00)00323-6","article-title":"Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection","volume":"746","author":"Avenoso","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103307_bib0024","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103307_bib0025","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1073\/pnas.77.8.4961","article-title":"Fecalase: a model for activation of dietary glycosides to mutagens by intestinal flora","volume":"77","author":"Tamura","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103307_bib0026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02976558","article-title":"Fecal metabolic activities of herbal components to bioactive compounds","volume":"25","author":"Lee","year":"2002","journal-title":"Arch Pharm Res"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103307_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180745","article-title":"Regulation of gut luminal serotonin by commensal microbiota in mice","volume":"12","author":"Hata","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103307_bib0028","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mp.2012.77","article-title":"The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner","volume":"18","author":"Clarke","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1214\/aoms\/1177729885","article-title":"Sample criteria for testing outlying observations","volume":"21","author":"Grubbs","year":"1950","journal-title":"Ann Math Stat"},{"key":"10.1016\/j.ebiom.2021.103307_bib0030","article-title":"Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function","author":"Cussotto","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ebiom.2021.103307_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-019-0540-4","article-title":"Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut","author":"Fung","year":"2019","journal-title":"Nat Microbiol"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103307_bib0032","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103307_bib0033","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jcmgh.2018.06.005","article-title":"Hidden dangers of antibiotic use: increased gut permeability mediated by increased pancreatic proteases reaching the colon","volume":"6","author":"Spiller","year":"2018","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103307_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144854","article-title":"Antibiotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on antibiotic class","volume":"10","author":"Tulstrup","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/dmd.108.023721","article-title":"Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice","volume":"37","author":"Cui","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103307_bib0036","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/dmd.31.3.326","article-title":"Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family","volume":"31","author":"Shelby","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103307_bib0037","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1089\/omi.2014.0018","article-title":"Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics","volume":"18","author":"ElRakaiby","year":"2014","journal-title":"OMICS"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0038","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1757-4749-4-16","article-title":"Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes","volume":"4","author":"Saad","year":"2012","journal-title":"Gut Pathogens"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103307_bib0039","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.115.067504","article-title":"Regulation of hepatic drug-metabolizing enzymes in germ-free mice by conventionalization and probiotics","volume":"44","author":"Selwyn","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103307_bib0040","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0090-9556(24)13663-X","article-title":"Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin","volume":"28","author":"Ledirac","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103307_bib0041","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","article-title":"Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios","volume":"32","author":"Williams","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0042","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ebiom.2021.103307_bib0043","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.1038\/srep09627","article-title":"Identifying and applying a highly selective probe to simultaneously determine the O-glucuronidation activity of human UGT1A3 and UGT1A4","volume":"5","author":"Jiang","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103307_bib0044","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0090-9556(25)06808-4","article-title":"Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine","volume":"15","author":"Mistry","year":"1987","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0016-5085(99)70239-8","article-title":"UDP-glucuronosyltransferase activity in human liver and colon","volume":"116","author":"Strassburg","year":"1999","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103307_bib0046","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the dependency of cellular protein levels on mRNA abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103307_bib0047","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1124\/dmd.109.027227","article-title":"Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers","volume":"37","author":"Izukawa","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103307_bib0048","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1124\/dmd.112.045625","article-title":"Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues","volume":"40","author":"Oda","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0049","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/dmd.111.042259","article-title":"Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities","volume":"40","author":"Ohtsuki","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.108.023598","article-title":"Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction","volume":"37","author":"Ohno","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0051","doi-asserted-by":"crossref","first-page":"e00002","DOI":"10.1002\/prp2.2","article-title":"Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: similarity with glucuronidation in human liver microsomes","volume":"1","author":"Kutsuno","year":"2013","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ebiom.2021.103307_bib0052","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bcp.2016.09.023","article-title":"Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin","volume":"122","author":"Kim","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103307_bib0053","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/HJH.0000000000000773","article-title":"Effects of orally administered antibiotics on the bioavailability of amlodipine: gut microbiota-mediated drug interaction","volume":"34","author":"Yoo","year":"2016","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103307_bib0054","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/dmd.117.077222","article-title":"Effect of probiotics on pharmacokinetics of orally administered acetaminophen in mice","volume":"46","author":"Kim","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"6161","key":"10.1016\/j.ebiom.2021.103307_bib0055","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103307_bib0056","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ebiom.2021.103307_bib0057","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2017.07.022","article-title":"Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia","volume":"193","author":"Lu","year":"2018","journal-title":"Schizophr Res"},{"key":"10.1016\/j.ebiom.2021.103307_bib0058","first-page":"348","article-title":"Is there a place for therapeutic drug monitoring of olanzapine?","volume":"3","author":"Flanagan","year":"2011","journal-title":"Clin Pharmacist"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:04:48Z","timestamp":1762455888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":58,"alternative-id":["S2352396421001006"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103307","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The gut microbiome influences the bioavailability of olanzapine in rats","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103307"}}